BTK and Waldenstrom macroglobulinemia: Ibrutinib is a first-in-class small molecule inhibitor of Bruton’s tyrosine kinase (BTK) and is used to treat B cell cancers such as mantle cell lymphoma[34] and Waldenström’s macroglobulinemia[35].